<DOC>
	<DOCNO>NCT02520245</DOCNO>
	<brief_summary>This study design collect long-term follow-up information patient receive REGN2810 clinical study allow re-treatment eligible patient .</brief_summary>
	<brief_title>Companion Study Patients Who Completed Participation REGN2810 ( Anti-PD-1 ) Clinical Study</brief_title>
	<detailed_description />
	<criteria>The target population study patient participate REGN2810 clinical study . Inclusion Criteria Patients Receiving Retreatment : 1 . Tolerated prior treatment REGN2810 unacceptable toxicity ( except select reversible irAEs ) require discontinuation REGN2810 2 . Developed document progressive disease first demonstrate clinical benefit initial treatment 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 1 4 . ≥18 year old 5 . Hepatic function : Total bilirubin ≤ 1.5 x upper limit normal ( ULN ; liver metastases ≤ 3 x ULN ) Transaminases ≤ 3 x ULN ( ≤ 5.0 x ULN , liver metastasis ) Alkaline phosphatase ( ALP ) ≤ 2.5 x ULN ( ≤ 5.0 x ULN , liver metastasis ) For patient hepatic metastasis hepatic malignancy , exclude patient concomitant 3 x ULN ≤ aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) ≤ 5 x ULN 1.5 x ULN ≤ total bilirubin ≤ 3 x ULN 6 . Renal function : Serum creatinine ≤ 1.5 x ULN 7 . Bone marrow function : Hemoglobin ≥ 9.0 g/dL Absolute neutrophil count ( ANC ) ≥ 1.5 x 10^9/L Platelet count ≥ 75 x 10^9/L Inclusion Criteria Patients Will Receive Retreatment : Patients must complete participation REGN2810 clinical study . A patient meet follow criterion exclude receive retreatment REGN2810 : 1 . Ongoing recent ( within 5 year ) evidence significant autoimmune disease require treatment systemic immunosuppressive treatment , may suggest risk irAEs . 2 . Patients experience irAE participate another REGN2810 protocol unable corticosteroid dose reduce &lt; 10 mg per day prednisone equivalent within 12 week toxicity . 3 . Patients develop ≥ Grade 2 uveitis prior REGN2810 protocol 4 . Immunosuppressive corticosteroid dos ( &gt; 10 mg prednisone daily equivalent ) within 4 week prior first dose REGN2810 5 . Active infection require therapy , include know infection human immunodeficiency virus , active infection hepatitis B hepatitis C virus . 6 . History pneumonitis within last 5 year . 7 . Any investigational antitumor treatment within 30 day prior initial administration REGN2810 . 8 . History document allergic reaction acute hypersensitivity reaction attribute Grade ≥ 3 severity directly follow REGN2810 infusion 9 . Known allergy doxycycline tetracycline . ( precaution due presence trace component REGN2810 ) 10 . Breastfeeding 11 . Positive serum pregnancy test 12 . History within last 5 year invasive malignancy one treat study , exception resected/ablated basal squamouscell carcinoma skin carcinoma situ cervix , local tumor consider cured local treatment . 13 . Acute chronic psychiatric problem , evaluation investigator , make patient ineligible participation 14 . Unwilling practice adequate contraception study 6 month last dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>